Our Pricing

Wegovy to Mounjaro: Complete UK Transition Guide for All Doses

Switching from Wegovy to Mounjaro is a common decision for patients seeking enhanced weight loss outcomes or better tolerance profiles. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) are GLP-1 receptor agonists licensed by the MHRA for chronic weight management, but Mounjaro's dual GIP/GLP-1 mechanism has demonstrated superior average weight reduction in head-to-head trials [1]. At Cured Pharmacy, our UK-registered clinical team provides expert guidance on transitioning safely between these treatments, with transparent pricing from £124.99 and all doses from 0.25mg to 2.4mg available subject to prescriber approval.

Why Patients Switch from Wegovy to Mounjaro

Clinical evidence from the SURPASS-2 trial showed that tirzepatide (Mounjaro) delivered greater mean weight loss compared to semaglutide 1mg — patients on the highest tirzepatide dose (15mg) achieved up to 22.5% body weight reduction versus 14.9% with semaglutide after 40 weeks [1]. This superior efficacy drives many patients to transition from Wegovy to Mounjaro once they plateau or seek accelerated results.

Tolerability is another key factor. While both medications share gastrointestinal side effects, some patients report better symptom management with Mounjaro's dual incretin action [2]. The slower dose escalation schedule for Mounjaro (starting at 2.5mg for four weeks) may also reduce initial nausea compared to Wegovy's 0.25mg weekly starting dose. Every patient responds differently, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that switching decisions should always be guided by a UK prescriber following thorough clinical assessment.

Supply considerations also influence transitions. During periods when Wegovy availability fluctuates, Mounjaro offers a clinically proven alternative within the same therapeutic class. At Cured Pharmacy, we maintain stock of all Wegovy and Mounjaro doses to ensure continuity of care, with pricing from £124.99 making the transition financially accessible for UK patients.

Clinical Evidence Supporting the Wegovy to Mounjaro Transition

The STEP programme established semaglutide's efficacy for weight management, with STEP 1 demonstrating 14.9% average weight loss at 68 weeks [3]. However, the SURPASS trials revealed tirzepatide's enhanced performance across all dose levels. In SURPASS-2, even the mid-range 10mg tirzepatide dose outperformed semaglutide 1mg, achieving 19.5% mean weight reduction [1]. This dose-response advantage means patients switching from Wegovy to Mounjaro often see renewed progress after weight loss stalls.

NICE guidelines recognise both medications for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities), and switching between GLP-1 therapies is supported when clinical benefit plateaus or tolerability issues arise [4]. Our UK clinical team assesses each transition request individually, ensuring the switch from Wegovy to Mounjaro aligns with your weight management goals and medical history.

Dose Equivalence: Matching Your Wegovy Dose When Transitioning to Mounjaro

There is no direct milligram-to-milligram equivalence when moving from Wegovy to Mounjaro, as semaglutide and tirzepatide have different pharmacokinetic profiles and receptor mechanisms. Wegovy reaches a maximum maintenance dose of 2.4mg weekly, while Mounjaro escalates to 15mg weekly for maximal weight loss. Clinical practice typically recommends starting Mounjaro at the 2.5mg dose regardless of your previous Wegovy dose, then titrating upward every four weeks as tolerated [2].

Patients currently on Wegovy 2.4mg should not assume they will begin Mounjaro at a similarly high dose. The standard Mounjaro titration schedule — 2.5mg for four weeks, then 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg — allows your body to adapt to the dual GIP/GLP-1 action while minimising gastrointestinal side effects. This gradual approach when switching from Wegovy to Mounjaro is essential for safety and adherence.

If you experience intolerable side effects at any Mounjaro dose level, your prescriber may hold the dose for an additional four weeks before escalating, or step down temporarily. At Cured Pharmacy, all Mounjaro doses from 2.5mg to 15mg are available from £124.99 and our clinical team provides ongoing support throughout your titration journey.

How to Safely Transition from Wegovy to Mounjaro in the UK

The transition from Wegovy to Mounjaro requires careful timing to avoid overlapping GLP-1 receptor activity. Most UK prescribers recommend administering your final Wegovy dose, waiting seven days (one full week), then starting Mounjaro 2.5mg on day eight [2]. This washout period accounts for semaglutide's half-life of approximately one week, reducing the risk of compounded gastrointestinal effects.

Before switching, complete a clinical assessment with a UK-registered prescriber to confirm Mounjaro is appropriate for your medical history. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease [4]. Our online consultation at Cured Pharmacy takes under three minutes and is reviewed by GPhC-registered clinicians who specialise in weight management.

Once approved, you will receive your Mounjaro 2.5mg KwikPen with full injection instructions. Inject subcutaneously in the abdomen, thigh, or upper arm once weekly on the same day each week. Continue this dose for four weeks before escalating to 5mg, following the standard titration schedule. Patients switching from Wegovy to Mounjaro should maintain their reduced-calorie diet and increased physical activity programme to optimise weight loss outcomes.

Managing Side Effects During the Wegovy to Mounjaro Switch

Even if you tolerated Wegovy well, expect potential gastrointestinal side effects when starting Mounjaro — nausea, diarrhoea, constipation, and abdominal discomfort are common during the initial weeks [2]. These symptoms typically subside as your body adapts to tirzepatide. Eating smaller, more frequent meals and avoiding high-fat foods can mitigate nausea.

If side effects persist beyond the first month or become severe, contact your prescriber before your next dose escalation. Delaying the increase from 2.5mg to 5mg by an additional four weeks is a safe strategy to improve tolerability. Our clinical team at Cured Pharmacy is available via phone (+44 116 4646009) to discuss any concerns during your transition from Wegovy to Mounjaro.

Wegovy to Mounjaro: Expected Weight Loss Outcomes After Switching

Patients who switch from Wegovy to Mounjaro often report renewed weight loss, particularly if they had plateaued on semaglutide. In the SURPASS-2 trial, participants on tirzepatide 15mg lost an average of 5.5kg more than those on semaglutide 1mg over 40 weeks [1]. While individual results vary, this data suggests Mounjaro's dual incretin action may overcome weight loss resistance seen with single-receptor GLP-1 agonists.

Timeframes for visible results depend on your starting dose and adherence to lifestyle modifications. Most patients notice appetite suppression within the first two weeks of Mounjaro 2.5mg, with measurable weight loss (1-2kg) by week four. As you titrate upward to 5mg, 7.5mg, and beyond, weight loss typically accelerates — clinical trials showed peak efficacy at the 10mg and 15mg maintenance doses [1].

It is important to set realistic expectations when transitioning from Wegovy to Mounjaro. Not all patients will experience the average 22.5% weight reduction seen in trials; factors including baseline BMI, dietary adherence, physical activity, and metabolic health all influence outcomes. Our UK clinical team recommends regular weight and waist circumference monitoring, with follow-up assessments every 12 weeks to evaluate treatment response and adjust your plan as needed.

Cost Comparison: Wegovy to Mounjaro Pricing Across UK Pharmacies

Pricing transparency is essential when considering the switch from Wegovy to Mounjaro. At Cured Pharmacy, Wegovy starts from £124.99 (with £20 off your first order using code Weightlossnew), while Mounjaro begins at £124.99 for the 2.5mg starting dose. Both treatments require ongoing monthly prescriptions, so budgeting for long-term use is critical.

Unlike some UK pharmacies that display pricing only after consultation, Cured Pharmacy shows all costs upfront. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) believes patients deserve full financial clarity before committing to treatment. We guarantee the lowest UK prices for both Wegovy and Mounjaro, with discreet packaging and next-day delivery included at no extra charge.

When calculating the total cost of switching from Wegovy to Mounjaro, factor in the titration period. You will spend approximately four weeks on each dose level (2.5mg, 5mg, 7.5mg, etc.) before reaching your maintenance dose. While Mounjaro's per-pen price is higher than Wegovy, many patients find the enhanced weight loss outcomes justify the investment. Our clinical team can discuss cost-effective dosing strategies during your online assessment.

Wegovy to Mounjaro: Insurance and NHS Availability in the UK

NHS prescription of Mounjaro for weight management is limited to specialist weight management services in England, following NICE guidance [4]. Most UK patients access Mounjaro privately, either through online pharmacies like Cured Pharmacy or in-person clinics. Wegovy availability via NHS prescription has also been restricted due to supply constraints, though this is gradually improving.

Private health insurance coverage for GLP-1 weight loss medications varies by provider and policy. Some insurers reimburse Wegovy or Mounjaro if prescribed for obesity with documented comorbidities such as type 2 diabetes or hypertension. Check your policy terms and request a detailed receipt from Cured Pharmacy for reimbursement claims. Our GPhC registration (9012511) and full prescriber details are included on all invoices to support insurance submissions.

Ongoing Support for Your Wegovy to Mounjaro Transition at Cured Pharmacy

Switching weight loss medications is a significant clinical decision that benefits from expert guidance. At Cured Pharmacy, every patient transitioning from Wegovy to Mounjaro receives a comprehensive online consultation with a UK-registered prescriber, personalised dosing recommendations, and access to our clinical support team throughout treatment. We stock all doses from 0.25mg to 15mg, ensuring seamless supply continuity.

Our service includes free follow-up consultations every 12 weeks to assess progress, adjust doses, and address any side effects or concerns. If Mounjaro proves unsuitable, we can facilitate a return to Wegovy or explore alternative weight management options such as Saxenda (liraglutide) or oral semaglutide tablets. This flexibility ensures you receive the most effective treatment for your individual needs.

Starting your transition from Wegovy to Mounjaro is straightforward: complete our three-minute online assessment, receive prescriber approval within 24 hours, and have your medication delivered discreetly to your door the next day. With transparent pricing from £124.99 the lowest UK prices guaranteed, and expert clinical oversight, Cured Pharmacy makes switching safe, affordable, and convenient. Contact our team on (+44) 116 4646009 or begin your assessment online today.

Why Choose Cured Pharmacy for Wegovy to Mounjaro Transitions?

Cured Pharmacy is a fully registered UK online pharmacy (GPhC 9012511) led by superintendent pharmacist Tarun Kumar (GPhC 2233073), with a dedicated focus on evidence-based weight management. We supply only genuine, UK-licensed medications sourced from reputable wholesalers, ensuring every Wegovy and Mounjaro pen meets MHRA quality standards.

Our transparent pricing model means no hidden fees — the price you see is the price you pay, including prescriber consultation, medication, and next-day delivery. We offer the cheapest UK prices for both Wegovy and Mounjaro, with additional savings available through discount codes such as Weightlossnew (£20 off first orders). All prescriptions are issued by UK-registered clinicians following thorough assessment, and our discreet packaging protects your privacy at every stage.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.